Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

1.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.

PMID:
16798415
[PubMed - indexed for MEDLINE]
2.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.

PMID:
14575823
[PubMed - indexed for MEDLINE]
3.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62. Epub 2005 Sep 19.

PMID:
16169682
[PubMed - indexed for MEDLINE]
4.

Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.

Urology. 2007 Mar;69(3):541-6.

PMID:
17382161
[PubMed - indexed for MEDLINE]
5.

Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?

Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):409-14.

PMID:
15667960
[PubMed - indexed for MEDLINE]
6.

Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002.

PMID:
15752878
[PubMed - indexed for MEDLINE]
7.

The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy.

Hodgson DC, Catton CN, Warde P, Gospodarowicz MK, Milosevic MF, McLean M B M, Catton P.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):957-63.

PMID:
11240236
[PubMed - indexed for MEDLINE]
8.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
[PubMed - indexed for MEDLINE]
10.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL.

J Urol. 2005 Mar;173(3):797-802.

PMID:
15711272
[PubMed - indexed for MEDLINE]
11.

Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):14-9.

PMID:
15629589
[PubMed - indexed for MEDLINE]
12.

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer.

Vicini FA, Kestin LL, Martinez AA.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):553-61.

PMID:
10524405
[PubMed - indexed for MEDLINE]
14.

Definitions of biochemical failure in prostate cancer following radiation therapy.

Taylor JM, Griffith KA, Sandler HM.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1212-9.

PMID:
11483331
[PubMed - indexed for MEDLINE]
16.
17.

Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.

Stock RG, Klein TJ, Cesaretti JA, Stone NN.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. doi: 10.1016/j.ijrobp.2008.08.049. Epub 2008 Dec 10.

PMID:
19084351
[PubMed - indexed for MEDLINE]
18.

Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.

Pickles T; British Columbia Cancer Agency Prostate Cohort Outcomes Initiative.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1355-9. Epub 2006 Jan 10.

PMID:
16406391
[PubMed - indexed for MEDLINE]
19.

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.

J Urol. 2001 Apr;165(4):1146-51.

PMID:
11257657
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk